

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

UPDATE ON POSITIVE PROFIT ALERT

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 15 June 2018 (the “**Announcement**”). Capitalized terms used herein shall bear the same meanings as defined in the Announcement, unless otherwise stated.

The Board wishes to update the Shareholders and potential investors that the Company is in the process of finalizing its annual results for the year ended 31 March 2018. According to the Board’s latest assessment and based on the information currently available to it, including the Management Accounts, the Group expects to record an increase in profit of about HK\$11 million instead of about HK\$30 million as stated in the Announcement, mainly due to an accounting treatment related to recording of an unrealized loss on the available-for-sale investments of about HK\$21 million.

The Company is still in the process of finalizing the annual results of the Group for the year ended 31 March 2018. The information as set out above is only based on the latest assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalized and are subject to audit or further review by the Company’s auditor. The annual results of the Company for the year ended 31 March 2018 are expected to be published on 29 June 2018.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 26 June 2018

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen, Mr. Liu Kwok Wah and Mr. Lu Zhiqiang and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

** For identification purpose only*